Comparing Monte Rosa Therapeutics (NASDAQ:GLUE) & Marker Therapeutics (NASDAQ:MRKR)

Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) and Marker Therapeutics (NASDAQ:MRKR – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Volatility & Risk

Monte Rosa Therapeutics has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500.

Earnings and Valuation

This table compares Monte Rosa Therapeutics and Marker Therapeutics”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Monte Rosa Therapeutics $123.67 million 6.01 -$38.63 million ($1.40) -6.22
Marker Therapeutics $3.55 million 5.42 -$12.16 million ($0.39) -2.96

Marker Therapeutics has lower revenue, but higher earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings for Monte Rosa Therapeutics and Marker Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Monte Rosa Therapeutics 1 2 8 1 2.75
Marker Therapeutics 1 1 2 0 2.25

Monte Rosa Therapeutics presently has a consensus target price of $26.44, suggesting a potential upside of 203.78%. Marker Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 766.55%. Given Marker Therapeutics’ higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than Monte Rosa Therapeutics.

Institutional & Insider Ownership

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Comparatively, 5.7% of Marker Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Monte Rosa Therapeutics and Marker Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Monte Rosa Therapeutics -186.24% -30.14% -20.35%
Marker Therapeutics N/A -64.23% -53.79%

Summary

Monte Rosa Therapeutics beats Marker Therapeutics on 9 of the 15 factors compared between the two stocks.

About Monte Rosa Therapeutics

(Get Free Report)

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degraders, medicines designed to direct disease-associated proteins for disposal by the cell. Its discovery platform combines computational and experimental methods to identify and develop these potential treatments. The company’s research has included programs for cancer and immune-mediated diseases. Its pipeline includes MRT-6160, a VAV1 degrader being developed for autoimmune and inflammatory conditions, and MRT-8102, an investigational degrader targeting the NLRP3 inflammasome pathway.

About Marker Therapeutics

(Get Free Report)

Marker Therapeutics is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. Its platform aims to produce T cells that recognize multiple tumor-associated antigens, with the goal of helping them target cancer cells while reducing the risk that tumors evade treatment by losing a single antigen. The company’s pipeline includes multi-antigen-specific T-cell candidates for blood cancers. Its programs have included MT-601, studied for lymphoma, and MT-401, developed for acute myeloid leukemia and other hematologic malignancies.

Receive News & Ratings for Monte Rosa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monte Rosa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.